Table 1.
Patient Characteristics by Age at First OAC Prescription Redemption of OAC‐Naive Patients With AF (N=34 683)
| Characteristic, % (No.) | 60 to 69 y | 70 to 79 y | 80 y and Older | |||
|---|---|---|---|---|---|---|
| Warfarin | NOAC | Warfarin | NOAC | Warfarin | NOAC | |
| No. | 4332 | 6846 | 5387 | 8126 | 3653 | 6339 |
| Median time from first AF diagnosis to first OAC prescription, d (IQR) | 19 (4–546) | 8 (2–438) | 12 (4–230) | 7 (3–136) | 11 (5–162) | 9 (4–144) |
| Dabigatran | … | 46.1 (3156) | … | 39.1 (3178) | … | 32.8 (2078) |
| Apixaban | … | 28.3 (1940) | … | 32.2 (2618) | … | 39.4 (2496) |
| Rivaroxaban | … | 25.6 (1750) | … | 28.7 (2330) | … | 27.8 (1765) |
| Reduced‐dose NOAC | … | 9.0 (614) | … | 23.0 (1867) | … | 73.7 (4673) |
| Hospital stay within 30 d | 66.4 (2878) | 62.6 (4285) | 70.2 (3784) | 66.6 (5413) | 78.0 (2850) | 75.3 (4774) |
| Women | 35.6 (1543) | 37.8 (2585) | 43.9 (2367) | 46.9 (3815) | 55.5 (2027) | 62.1 (3939) |
| Mean age (SD) | 65.9 (2.7) | 65.9 (2.7) | 74.9 (2.8) | 74.7 (2.9) | 85.1 (3.8) | 86.1 (4.4) |
| Comorbidity | ||||||
| Mean CHA2DS2‐VASc score (SD) | 2.2 (1.2) | 2.1 (1.2) | 3.3 (1.3) | 3.1 (1.2) | 4.0 (1.2) | 3.9 (1.1) |
| Mean HAS‐BLED score (SD) | 2.0 (1.1) | 1.9 (1.0) | 2.5 (0.9) | 2.4 (0.9) | 2.6 (0.9) | 2.4 (0.9) |
| Mean Charlson Comorbidity Index score (SD) | 0.9 (1.4) | 0.8 (1.4) | 1.2 (1.6) | 1.1 (1.6) | 1.2 (1.6) | 1.3 (1.6) |
| Renal dysfunction | 6.5 (280) | 2.8 (189) | 8.7 (471) | 4.3 (351) | 10.0 (366) | 5.1 (323) |
| Myocardial infarction | 11.0 (475) | 8.0 (550) | 15.0 (809) | 10.2 (829) | 17.1 (625) | 13.0 (825) |
| Heart failure | 16.9 (731) | 11.2 (765) | 21.1 (1136) | 15.5 (1263) | 34.2 (1250) | 28.0 (1774) |
| Peripheral arterial disease | 6.1 (265) | 5.0 (341) | 10.4 (562) | 7.5 (608) | 10.5 (383) | 8.8 (559) |
| Vascular disease | 15.7 (679) | 12.1 (830) | 22.4 (1204) | 16.2 (1318) | 24.9 (908) | 19.8 (1254) |
| Diabetes mellitus | 14.2 (615) | 11.1 (761) | 13.6 (731) | 11.6 (940) | 11.6 (422) | 10.8 (686) |
| Hyperlipidemia | 15.7 (678) | 12.8 (877) | 17.4 (937) | 14.3 (1164) | 13.1 (478) | 10.6 (672) |
| Hypertension | 60.7 (2629) | 58.3 (3992) | 65.0 (3504) | 62.2 (5057) | 69.1 (2525) | 65.0 (4119) |
| Cancer | 4.6 (198) | 3.6 (246) | 6.8 (365) | 5.8 (472) | 6.3 (229) | 6.1 (385) |
| Chronic pulmonary disease | 12.2 (530) | 11.1 (760) | 17.2 (926) | 15.8 (1280) | 17.1 (625) | 17.4 (1103) |
| Prior bleeding | 10.3 (446) | 9.5 (651) | 13.0 (700) | 13.1 (1063) | 15.6 (569) | 14.7 (931) |
| Depression | 1.4 (60) | 1.3 (91) | 1.5 (79) | 1.7 (140) | 2.2 (80) | 2.9 (183) |
| Hospital‐diagnosed obesity | 10.2 (440) | 9.6 (657) | 8.0 (429) | 7.8 (634) | 4.8 (177) | 4.8 (305) |
| Smoking‐related diagnoses | 4.4 (192) | 4.7 (323) | 4.7 (254) | 5.0 (404) | 2.7 (99) | 3.7 (236) |
| Alcohol‐related abuse | 4.3 (186) | 4.6 (314) | 2.5 (132) | 3.2 (258) | 1.1 (42) | 1.2 (78) |
| Drug‐related abuse | 0.2 (7) | 0.2 (11) | 0.1 (8) | 0.2 (15) | 0.1 (5) | 0.2 (12) |
| Comedications | ||||||
| Clopidogrel | 3.8 (164) | 2.5 (173) | 4.5 (241) | 3.7 (298) | 4.6 (167) | 4.5 (284) |
| Aspirin | 39.2 (1696) | 34.1 (2337) | 45.8 (2466) | 38.0 (3085) | 49.8 (1821) | 44.5 (2821) |
| Loop diuretics | 16.9 (734) | 11.2 (768) | 21.2 (1143) | 15.7 (1272) | 34.2 (1250) | 28.1 (1779) |
| Nonloop diuretics | 33.0 (1428) | 32.6 (2233) | 39.7 (2137) | 38.1 (3093) | 45.4 (1658) | 42.1 (2669) |
| Digoxin | 5.5 (238) | 3.6 (248) | 6.6 (358) | 4.8 (387) | 9.2 (337) | 8.5 (541) |
| β‐Blockers | 47.0 (2035) | 38.8 (2656) | 44.2 (2380) | 37.9 (3078) | 45.3 (1655) | 37.8 (2395) |
| Calcium channel blockers | 29.4 (1275) | 27.0 (1848) | 32.5 (1751) | 31.1 (2529) | 37.2 (1358) | 32.7 (2075) |
| Verapamil | 4.0 (172) | 3.1 (212) | 3.0 (162) | 2.3 (186) | 2.4 (86) | 2.4 (153) |
| Renin‐angiotensin inhibitors | 45.2 (1960) | 44.3 (3034) | 47.9 (2578) | 47.2 (3839) | 50.5 (1843) | 46.0 (2915) |
| Statin | 37.4 (1619) | 35.3 (2415) | 43.3 (2333) | 38.6 (3139) | 34.4 (1256) | 30.3 (1921) |
| NSAIDs | 23.3 (1008) | 23.9 (1639) | 23.1 (1242) | 23.3 (1895) | 18.9 (691) | 18.4 (1169) |
AF indicates atrial fibrillation; IQR, interquartile range; NOAC, nonvitamin K antagonist oral anticoagulant; NSAIDs, nonsteroidal anti‐inflammatory drugs; OAC, oral anticoagulant.